Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid... (

Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis

Date:11/21/2007

- ACTEMRA(R) is the first humanized interleukin-6 (IL-6)

receptor-inhibiting monoclonal antibody seeking approval to treat

rheumatoid arthritis -

NUTLEY, N.J., Nov. 21 /PRNewswire/ -- Roche announced today the submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval to market ACTEMRA(R) (tocilizumab) to reduce the signs and symptoms in adults with moderate to severe rheumatoid arthritis (RA).

"The filing for ACTEMRA represents a significant milestone for Roche, and brings us another step closer to making this important therapy available to the millions of patients in the United States who suffer from the agonizing pain and debilitating effects associated with rheumatoid arthritis," said George Abercrombie, President and CEO, Hoffmann-La Roche Inc.

ACTEMRA is the first humanized interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody and represents a novel mechanism of action to treat RA. Research suggests that reducing the activity of IL-6, one of several key cytokines involved in the inflammatory process, may reduce inflammation of the joints and relieve certain systemic effects of RA.

The BLA submission to the FDA is based on results from five international Phase III studies which demonstrated ACTEMRA as monotherapy or in combination with disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate significantly reduced the signs and symptoms of rheumatoid arthritis as measured by ACR -- as well as achieving disease activity score (DAS) remission -- compared to DMARD therapies alone. Furthermore, patients who had previously failed anti-tumor necrosis factor (anti-TNF) treatments also showed significant improvement in signs and symptoms of RA after treatment with ACTEMRA.

Roche will file a Marketing Authorization Application (MAA) for ACTEMRA with the European Medicines Agency (EMEA) in early December.

Ab
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
3. Rochester Medical Anti-Infection Foley Catheter Demonstrates Effectiveness in Randomized Trial
4. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
5. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
6. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Two Pivotal Phase III Studies for Roches ACTEMRA(TM) (tocilizumab) Demonstrate Significant Improvement in Rheumatoid Arthritis Symptoms
9. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
10. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
11. Vanda Pharmaceuticals Submits Iloperidone New Drug Application

Post Your Comments:

(Date:11/30/2009)... , NEW YORK, Nov. 30 Reportli...rt is available in its catalogue: ,, Outsourci...4) ,, http://www.reportlinker.com/p0165747/Ou... ,, Report Description ,, Medical devices ...ector with an estimated size of $250 billion in 20...

(Date:11/30/2009)... MT. LAUREL, N.J., Nov. 30 /PRNewswire-FirstCall...rovider of technology-enabled clinical documentati... at the Radiological Society of North America (RSN...r Radiology, the product leverages SpeechQ(TM), th...on application used by thousands of radiologists. ...

(Date:11/30/2009)..., COVINA, Calif., Nov. 30 StemCyt...ialization agreement with Academia Sinica, the Nat...y methods and Intellectual Property (IP) related t... This method and IP was pioneered by a team led b...mia Sinica. Professor Lin is currently the exclus...

[0] Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014)[0] MedQuist Features SpeechQ VTB for Radiology Solution at RSNA Convention [0] StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke

... Inc.,(Nasdaq: OREX ) today announced changes to...s on its late-stage obesity programs and realign i...se changes are as follows: , -- The explora...(zonisamide and olanzapine to mitigate antipsychot...e and naltrexone to reduce symptoms of obsessive-,...

...ublished in,EuroIntervention showed that the expec...r with the MitraClip(R) system to correct mitral r...y significant mitral stenosis. Additionally,with t...d with the,MitraClip(R) system required surgery fo...rences were reported between the use of one or two...

Other Medicine Technology:Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 2 Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team 3 Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 2 Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 3 Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System 4

Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System

(Date:12/1/2009)... Amadeus will operate as a division of Xybion...lls, NJ (PRWEB) December 1, 2009 -- Xybion Corpora...uisition of all operating assets of Quebec City ba... of enterprise governance, risk, compliance and qu... a corporate performance management organization h...

(Date:12/1/2009)... Recent Reviews In Major Peer Review Journals...ising New Developments For The Evidence-Based Asse...iculties. Some Of The Most Recent Are Listed Below...009 -- Review written by: Leesa V. Huang Ph.D. for...No. 3 November 2009. A nice synopsis of this artic...

(Date:12/1/2009)... The Daniel Jordan Fiddle Foundation, a natio...p, advocate for, and support programs and services...isorders (ASD), has released a free informational ...zures: How To Recognize The Signs and Basic First... New York, NY (PRWEB) December 1, 2009 -- Statisti...

(Date:12/1/2009)...inn., Dec. 1 "The patient will see... for Blue Cross and Blue Shield of Minnesota,s 10,...he first Minnesotans - and the first in the contin...e(SM). Online Care Anywhere allows patients to acc...ng onto a computer or picking up the phone. Blue C...

(Date:12/1/2009)..., SHENZHEN, China, Dec. 1 /PRNewswire-Asia-Fi...SE: NPD ) ("Nepstar" or "the Company"), the larg...umber of directly operated stores,today announced...rter ended,September 30, 2009. ,, Financi...terminated a voting rights assignment agreement,w...

[0] Xybion Acquires Amadeus, a Leader in Governance, Risk, Compliance and Quality Management (GRC) Solutions [0] Targeted Testing Receives Favorable Reviews On PADDS, Begins Nationwide Research Study On The Target Tests of Executive Functioning-OV [0] Daniel Jordan Fiddle Foundation for Adults with Autism Offers Free Epilepsy First-Aid Brochure [0] Blue Cross and Blue Shield of Minnesota and Fairview Health Services Launch Online Care Anywhere(TM)[0] China Nepstar Chain Drugstore Reports 92.1% Year-on-Year Increase in Operating Income for Third Quarter 2009

...estern University about the effects of epidural pa...at epidural analgesic given at the early stages of...n delivery. 728 pregnant ladies in their final ...s of labor tended to be in labor for less time and...

...d in traditional Indian medicine to treat diabetes...in a manner similar to prescription drugs. The ...salacia oblonga, which is native to regions of Ind..., the sugar that circulates throughout the body. I...

...ffect of diseases on contact with children it was ...s likely to get the kind of affection other kids r... HIV-positive parents report avoided certain types...en their own conditions. Researchers talked wit...

...dden emotional stress can result in severe but rev...c heart attack.// Stress cardiomyopathy is oft...According to the researchers, patients have actual...ypical heart attack including chest pain, fluid in...

...betes begins in Chennai today. The theme for the c...tions //and over 1000 doctors and researchers will...ld. The world congress for diabetes is held...three-day event that draws support from World Heal...

...dy researchers say the arthritis drug rofecoxib (V...k. For the study researchers looked at health reco...er had a heart attack when the research started. A...xicam, and the COX-2 inhibitor celecoxib (Celebrex...

Other Medicine News:

Epidural given in early labor may not lead to caesarian birth Herb Found To Be Effective In Controlling Blood Sugar Levels HIV-positive Parents Require More Counseling Sudden Stress Found To Mimic Heart Attack Symptoms Chennai Plays Hosts To The Diabetes World Congress Arthritis Drug – Rofecoxib , Found To Increase Heart Attack Ris

Pacemaker Follow-Up Service

PROTG® GPS™ Self-Expanding Nitinol Stent

Assay Development

Coat-Block-Run Conjugation Kit pH 8-11

Medicine Products:

Pacemaker Follow-Up Service PROTG® GPS™ Self-Expanding Nitinol Stent Assay Development Coat-Block-Run Conjugation Kit pH 8-11

Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid...( - ACTEMRA(R) is the first h...),Health